A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

被引：14

作者：

Sekeres, Mikkael A. ^{[1
]}

Schuster, Michael W. ^{[2
]}

Joris, Magalie ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Kovacsovics, Tibor ^{[7
]}

Verma, Amit ^{[8
]}

Vyas, Paresh ^{[9
]}

Wang, Eunice S. ^{[10
]}

Ma, Weidong Wendy ^{[11
]}

Zeremski, Mirjana ^{[11
]}

Kudla, Arthur ^{[11
]}

Chan, Geoffrey ^{[11
]}

Zeidan, Amer M. ^{[12
,13
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[3] CHU Amiens Picardie, Amiens, France

[4] Med Klin Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hematol & Oncol, Bronx, NY 10467 USA

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Pfizer Oncol, New York, NY USA

[12] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[13] Yale Univ, Yale Canc Ctr, New Haven, CT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

177

引用

页数：6

共 50 条

[41] Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)
Rasmussen, Bengt
Gohring, Gudrun
Bernard, Elsa
Nilsson, Lars
Tobiasson, Magnus
Jadersten, Martin
Garelius, Hege
Dybedal, Ingunn
Gronbaek, Kirsten
Ejerblad, Elisabeth
Lorenz, Fryderyk
Flogegard, Max
Marcher, Claus Werenberg
oster Fernstrom, Annette
Cavelier, Lucia
Papaemmanuil, Elli
Ebeling, Freja
Kittang, Astrid Olsnes
Norgaard, Jan Maxwell
Saft, Leonie
Mollgard, Lars
Hellstrom-Lindberg, Eva
LEUKEMIA, 2022, 36 (05) : 1436 - 1439
[42] Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes
Izutsu, Koji
Ubukawa, Kumi
Morishita, Takanobu
Onishi, Yasushi
Ishizawa, Kenichi
Fujii, Yosuke
Kimura, Nobuyuki
Yokochi, Miyuu
Naoe, Tomoki
CANCER SCIENCE, 2024, 115 (04) : 1250 - 1260
[43] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Sekeres, Mikkael A.
Othus, Megan
List, Alan F.
Odenike, Olatoyosi
Stone, Richard M.
Gore, Steven D.
Litzow, Mark R.
Buckstein, Rena
Fang, Min
Roulston, Diane
Bloomfield, Clara D.
Moseley, Anna
Nazha, Aziz
Zhang, Yanming
Velasco, Mario R.
Gaur, Rakesh
Atallah, Ehab
Attar, Eyal C.
Cook, Elina K.
Cull, Alyssa H.
Rauh, Michael J.
Appelbaum, Frederick R.
Erba, Harry P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2745 - +
[44] Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
Vey, Norbert
Prebet, Thomas
Thalamas, Claire
Charbonnier, Aude
Rey, Jerome
Kloos, Ioana
Liu, Emily
Luan, Ying
Vezan, Remus
Graef, Thorsten
Recher, Christian
LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1880 - 1886
[45] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
Hiroshi Handa
June-Won Cheong
Yasushi Onishi
Hiroatsu Iida
Yukio Kobayashi
Hyeoung-Joon Kim
Tzeon-Jye Chiou
Koji Izutsu
Olga Tsukurov
Xiaofei Zhou
Helene Faessel
Ying Yuan
Farhad Sedarati
Douglas V. Faller
Akiko Kimura
Shang-Ju Wu
Journal of Hematology & Oncology, 15
[46] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
Handa, Hiroshi
Cheong, June-Won
Onishi, Yasushi
Iida, Hiroatsu
Kobayashi, Yukio
Kim, Hyeoung-Joon
Chiou, Tzeon-Jye
Izutsu, Koji
Tsukurov, Olga
Zhou, Xiaofei
Faessel, Helene
Yuan, Ying
Sedarati, Farhad
Faller, Douglas V.
Kimura, Akiko
Wu, Shang-Ju
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[47] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Zhou, Xiaofei
Mould, Diane R.
Zhao, Dan
Sekeres, Mikkael A.
Ades, Lionel
Swords, Ronan T.
Handa, Hiroshi
Fram, Robert J.
Faller, Douglas V.
Tsukurov, Olga
Gupta, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] ROLE OF ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA RECEIVING AZACITIDINE THERAPY
Avila, F.
Lorenzana, N.
Alonso, S.
Colado, E.
Bernal, T.
LEUKEMIA RESEARCH, 2017, 55 : S160 - S160
[49] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Sallman, David A.
Al Malki, Monzr M.
Asch, Adam S.
Wang, Eunice S.
Jurcic, Joseph G.
Bradley, Terrence J.
Flinn, Ian W.
Pollyea, Daniel A.
Kambhampati, Suman
Tanaka, Tiffany N.
Zeidner, Joshua F.
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Komrokji, Rami
Lancet, Jeffrey
Kantarjian, Hagop M.
Gu, Lin
Zhang, Yajia
Tan, Anderson
Chao, Mark
O'Hear, Carol
Ramsingh, Giridharan
Lal, Indu
Vyas, Paresh
Daver, Naval G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
[50] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
Navada, S. C.
Garcia-Manero, G.
Hearn, K.
Odchimar-Reissig, R.
Demakos, E.
Alvarado, Y.
Daver, N.
DiNardo, C.
Konopleva, M.
Borthakur, G.
Azarnia, N.
Silverman, L. R.
LEUKEMIA RESEARCH, 2015, 39 : S45 - S45

← 1 2 3 4 5 →